Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NeuroSearch finds some optimism

Following the failure of two major deals in 1999, with Bristol-Myers Squibb Co. and Pharmacia & Upjohn, the future of NeuroSearch A/S looked bleak. However, with products advancing through its pipeline and a fresh deal with Abbott Laboratories, NeuroSearch (CSE:NEUS) appears to have emerged from the

Read the full 468 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE